Una de las mayores metas de Life4me+ — prevenir nuevos casos de VIH y otras ITS, hepatitis C y tuberculosis.

El app ayuda a establecer una comunicación anónima entre médicos y personas vih+. Te permite organizar tu horario de toma de tratamiento de manera conveniente y fijar recordatorios personalizados que se pueden ocultar.

Atrás
9 enero 2017, 20:21
4109

Natco Pharma launches generic version of Hepatitis C drug in Nepal

Natco Pharma launches generic version of Hepatitis C drug in Nepal - imagen 1

Natco Pharma launches generic version of Hepatitis C drug in Nepal

Natco Pharma has launched Velpanat-a fixed dose combination drug containing sofosbuvir(400 mg) velpatasvir (100mg) for treatment of Hepatitis C in Nepal. The medication is sold by Gilead Sciences under brand name Epclusa and is the first pan-genotypic, single tablet regimen for the treatment of Hepatitis C. Natco has signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its Hep C medicines in 101 developing countries. Velpanat is priced at Rs 25,000 equivalent for a bottle of 28 tablets in Nepal. 

Autor: Marina Shegay

Comparte en las redes sociales